Purpose 3D printing (3DP) offers the potential to revolutionise the future production of drug delivery systems. In fused-deposition modelling (FDM) printing, a polymer is heated and extruded through a small tip and solidified on a build plate. FDM technology shows the potential of manufacturing personalized oral medicines at reduced cost and the ability to print patient-tailored dose formulations with pharmaceutical-grade polymers. Polyvinyl alcohol (PVA) is the main polymer used in pharmaceutics for FDM 3D printing, so there is merit in evaluating the factors that affect the drug release from these new systems. To do so, Quality-by-Design (QbD) can be implemented in these novel manufacturing technologies. Here, we prepared drug loaded caplets by FDM 3DP using PVA and one model drug (acetaminophen or caffeine) to evaluate the effect of caplet porosity, drug solubility and drug loading (critical material attributes, CMAs) on the drug release from the caplets. Methods Drug-loaded PVA filaments were obtained by hot melt extrusion using a filament extruder. A commercial PVA filament was cut into small pieces, milled in a grinder and mixed in a mortar and pestle with acetaminophen or caffeine until no agglomerated particles of drug or polymer were seen (theoretical drug contents were 5 or 10% w/w for each drug). The mixture of drug and PVA was then extruded using a single-screw filament extruder, Noztec Pro hot melt extruder (temperature 180 °C, nozzle diameter 1.75 mm). The extruded filaments obtained were protected from light and kept in a vacuum desiccator until printing. Caplets were fabricated from the drug-loaded filaments with a standard FDM 3D printer, MakerBot Replicator 2X. The templates used to print the caplets was designed with AutoCAD 2014® (Autodesk Inc., USA) and exported as a stereolithography file (.stl) into the 3D printer software ( MakerBot Inc., USA). The selected 3D geometry was a size 4 capsule-shaped tablet, 14.30mm length x 5.30mm diameter. Micropore volume of the filaments and the printed tablets was determined as the total volume of pores >0.1 μm in diameter, using an Autopore IV 9500 apparatus (Micromeritics, USA) over the pressure range 0.01-14.00 MPa. Drug release from the 3DP tablets was determined in a USP II apparatus (Pharmatest, Germany) simulating the environment conditions of the fasted GI tract. Briefly, the caplets were placed for 1 h into 900 mL of 0.1 M HCl, which simulates gastric residence time, and subsequently into 950 mL of modified Hanks based dynamic physiological dissolution medium for 35 min (pH 5.6 to 7), which is converted by addition of 50mL of solution in1000 mL of modified Krebs buffer (pH 7 to 7.4 and then to 6.5). The physiological buffers were pH controlled by an Auto pH TM system.
Results
The 3D printer was found to produce caplets with a high degree of repeatability of weight and physical dimension. Dissolution tests of the different formulations performed under biorelevant conditions show similar drug dissolution profiles, reaching 100% drug release in less than 480min. Drug release begins in the gastric phase (acid medium) and continues in the intestinal phase (biorelevant bicarbonate buffers) independently of the nature or pH of the dissolution media. The drug release rate did not appear to be influenced by the caplet microstructure (porosity). Drug release profiles from caffeine formulations are slightly faster than those from acetaminophen formulations, attributable to the higher water solubility of caffeine. For formulations incorporating the same drug, the release is faster when the drug loading is higher. Solubility and percentage of the drug in to the filaments appear as CMAs of the PVA-based 3D printed formulations.
Conclusion
We have demonstrated the feasibility of using hot melt extrusion to obtain filament that can be printed by FDM 3DP to fabricate drugloaded caplets. Drug release tests in biorelevant media showed drug release was faster from formulations incorporating those drugs with higher solubility and at higher concentrations. Studies of caplet porosity did not help to explain the different drug release rate profiles, where the drug dissolution is driven by erosion-mediated process. The results suggest that the combination of hot melt extrusion and FDM 3DP could offer a potential new method of manufacture for personalised-dose medicines and/or for tablets prepared at the point of dispensation/use. 3D printing technologies are innovative and totally computer-controlled, their development in the pharmaceutical field may be easily linked to the adoption of QbD goals.
